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Background
A huge volume of somatic mutations have been generated
through large cancer genome sequencing projects such as
The Cancer Genome Atlas (TCGA) and the International
Cancer Genome Consortium (ICGC). However, under-
standing the functional consequences of somatic muta-
tions in cancer and translating the results into clinical use
remains a major challenge in cancer genomic studies.
Thanks to the rapid development of structural genomic
technologies, such as X-ray and NMR, large amounts of
protein structure data have been generated during the past
decade, which enables us to map somatic mutations to
protein functional features (i.e., protein-ligand binding
sites) and investigate their potential impacts[1,2].
Materials and methods
In this study, we developed SGDriver, a structural geno-
mics-based approach that incorporates protein-ligand
binding sites information into the somatic missense muta-
tion data to help understand the pathophysiological role of
variations and prioritize putative druggable mutations
using a Bayes inference statistical framework. We applied
SGDriver to 746,631 missense mutations across 16 major
cancer types from TCGA.
Results
We found 251 genes enriched with ligand binding site
mutations in their protein products with false discovery
rate less than 0.05, including 43 Cancer Gene Census
(CGC) genes. Furthermore, drug-gene network analysis
identifies ~100 druggable anticancer targets using the data
from DrugBank, Therapeutics Target Database, and
PharmGKB databases. Finally, bioinformatics analysis
using Connectivity Map data identified several existing
drugs that may be potentially repurposed for precision
cancer therapy by targeting cancer driver gene products
identified by our SGDriver method. In summary, this
study provides a novel computational approach to identify
new druggable mutations for precision cancer medicine.
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